If You Invested in Waldencast plc Warrant (WALDW)
See the WALDW overviewWhat $1,000 or $10,000 in WALDW Was Worth at Its Last Close
Real historical value by amount invested and how long before the last close| If you invested | 1 year before | 5 years before | 10 years before | Since May 11, 2021 |
|---|---|---|---|---|
| $1,000 | $223 -78% | $7.88 -99% | — | $8.93 -99% |
| $10,000 | $2,233 -78% | $79 -99% | — | $89 -99% |
Based on real historical closing prices adjusted for stock splits, without dividends, through 2026-10-02. Figures with dividends reinvest each cash dividend at the previous close less the dividend, before taxes. Past performance does not guarantee future results.
Custom Calculation
Choose your own date and amount for WALDW$1,000 Investment Over Time
WALDW vs S&P 500Year-by-Year Returns
WALDW annual performance| Year | Start Price | End Price | Annual Return | Cumulative |
|---|---|---|---|---|
| 2021May 11, 2021 to Dec 31, 2021 | $0.75 | $1.21 | +61.3% | +61.3% |
| 2022 | $1.21 | $0.62 | -48.8% | -17.3% |
| 2023 | $0.62 | $0.97 | +56.5% | +29.3% |
| 2024 | $0.97 | $0.17 | -82.5% | -77.3% |
| 2025Dec 31, 2024 to Dec 23, 2025 | $0.17 | $0.04 | -76.5% | -94.7% |
| 2026Dec 23, 2025 to Oct 2, 2026 | $0.04 | $0.0067 | -83.3% | -99.1% |
About Waldencast plc Warrant
NASDAQ
Waldencast plc (WALDW) is described as a beauty and wellness operating platform within the manufacturing sector, classified under all other miscellaneous chemical product and preparation manufacturing. According to available information, the company focuses on brands and products in the broader beauty and skin health space, with activities that include developing, marketing, and selling beauty-related formulations.
The company is organized into two reportable segments: Obagi Medical and Milk Makeup. The Obagi Medical segment is engaged in developing, marketing, and selling skin health products under the Obagi Medical brand. The Milk Makeup segment involves developing, marketing, and selling cosmetics, skincare, and other beauty products. Based on disclosed segment information, Waldencast plc indicates that a significant portion of its revenue is associated with the Obagi Medical segment, underscoring the importance of skin health products within its overall business.
Waldencast plc is a foreign private issuer that reports to the U.S. Securities and Exchange Commission on Form 20-F and Form 6-K. The company has identified its principal executive office in London, United Kingdom. As a filer under the Securities Exchange Act of 1934, it periodically furnishes current reports on Form 6-K to provide updates on business developments and regulatory or commercial milestones.
Business segments and brand focus
The Obagi Medical segment centers on skin health products. In a Form 6-K current report, Waldencast plc announced that it had issued an announcement titled “Waldencast Announces FDA Approval of Obagi® saypha® MagIQ™ Injectable Hyaluronic Acid Gel Under the Obagi Medical Brand.” This highlights that the Obagi Medical segment includes products that may be subject to regulatory review and approval, such as injectable hyaluronic acid gel formulations under the Obagi brand.
The Milk Makeup segment includes cosmetics, skincare, and other beauty products. While detailed product lists are not provided in the available materials, the description of this segment emphasizes that it is focused on beauty and skincare offerings marketed under the Milk Makeup name.
Geographic and industry context
According to prior descriptive information, Waldencast plc generates a majority of its revenue from the North America region. Within the manufacturing sector, and specifically within all other miscellaneous chemical product and preparation manufacturing, its activities relate to the formulation and commercialization of beauty and skin health products, including those that may fall within regulated categories.
Regulatory and reporting profile
As indicated in its Form 6-K filings, Waldencast plc files under Form 20-F and uses Form 6-K to furnish press releases and business updates. One Form 6-K notes that the company provided business and financial updates and described progress on business priorities and initiatives to drive transformation, with a related press release attached as an exhibit. Another Form 6-K references the FDA approval of an Obagi-branded injectable hyaluronic acid gel product, also communicated via an attached company announcement.
These filings show that investors and observers can expect Waldencast plc to use SEC current reports to communicate material developments related to its brands, regulatory milestones, and broader business priorities.
Warrants and WALDW symbol
The symbol WALDW refers to warrants associated with Waldencast plc. The Form 6-K filings provided are identified as “Waldencast plc Warrant Current Report (Foreign Issuer),” indicating that these reports relate to the issuer whose warrants trade under WALDW. The filings themselves focus on company-level developments, and the warrant symbol provides a way for market participants to access exposure linked to Waldencast plc through derivative securities.
Evergreen considerations for investors and observers
From the available information, several structural aspects of Waldencast plc appear central and relatively stable over time:
- It operates as a beauty and wellness platform within the manufacturing sector.
- It reports two main segments: Obagi Medical and Milk Makeup.
- The Obagi Medical segment is associated with skin health products and, in at least one case, an FDA-approved injectable hyaluronic acid gel under the Obagi Medical brand.
- It is a foreign private issuer that uses Form 20-F and Form 6-K for SEC reporting.
- Its principal executive office is located in London, United Kingdom.
These elements provide a structural overview of how Waldencast plc presents its business and regulatory profile, without relying on time-sensitive performance metrics.
Similar Stocks
See how related companies performed
Frequently Asked Questions
Waldencast plc Warrant investment returns
How much was $1,000 invested in Waldencast plc Warrant worth at its last close?
If you invested $1,000 in Waldencast plc Warrant (WALDW) 5 years before its last close, on 2021-10-04, your investment was worth $7.88 on 2026-10-02, a -99.2% price return without dividends, growing at a compounded rate of -62.1% per year (CAGR).
Has Waldencast plc Warrant outperformed the S&P 500?
Comparison data requires at least 10 years of trading history. Use the calculator above to compare WALDW performance over available time periods.
What is Waldencast plc Warrant's average annual return?
The compound annual growth rate (CAGR) of WALDW’s share price over the 5 years to Oct 2, 2026 is -62.1%, without dividends. Individual years vary a great deal, and WALDW’s best recent full year was 2023 (+56.5%) while the worst was 2024 (-82.5%).
For informational and educational purposes only, not investment advice.
